When Can We Expect A Profit From Scholar Rock Holding Corporation (NASDAQ:SRRK)?
Scholar Rock Holding Corporation ( NASDAQ:SRRK ) is possibly approaching a major achievement in its business, so ...
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2024 Earnings Call Transcript
Operator: Good morning and welcome to Scholar Rock’s Fourth Quarter Financial Results and Business Update Call. All ...
Principal Financial Group Inc. Buys New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)
Principal Financial Group Inc. bought a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with ...
Business Wire21d
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Investing15d
Earnings call transcript: Scholar Rock Q4 2024 reveals EPS miss, stock rises
Scholar Rock reported a larger-than-expected loss, with EPS missing forecasts by a wide margin. The stock rose 1.84% in premarket trading, indicating positive investor sentiment. Anticipated ...
Morningstar27d
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...
Nasdaq27d
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...